Comparison of minimal residual leukemia immuno-phenotypes at primary diagnosis and after chemotherapy in patients with B-lineage acute lymphoblastic leukemia

doi:10.3969/j.issn.1673-8640.2016.06.007

Abstract

Abstract:

Objective To study the change of leukemia immuno-phenotypes before and after chemotherapy in patients with B-lineage acute lymphoblastic leukemia（B-ALL）,and to provide a reference for determining B-ALL minimal residual disease （MRD）by flow cytometry（FCM）. Methods The antigen positive rate and intensity changes of CD45,CD19,CD10,CD20,CD34,CD38,CD13 and CD33 determined by FCM were analyzed before and after chemotherapy among 226 B-ALL patients. Results The intensity changes from high to low were CD10,CD34,CD38,CD19,CD20 and CD45. The intensity changes of CD10 were significantly higher than those of CD38,CD19,CD20 and CD45（P<0.01）,the intensity changes of CD34 were higher than those of CD19,CD20 and CD45（P<0.01）,and the intensity changes of CD38 were higher than those of CD20 and CD45（P<0.01）. In the 33rd day of chemotherapy,the enhanced proportions of CD34 and CD45 expression were higher than those in the 15th day（P<0.05）. The changes of antigen positive rate from high to low were CD20,CD38,CD34,CD45,CD10 and CD19,and those of CD20 and CD38 were significantly higher than those of CD34,CD45,CD10 and CD19（P<0.01）. In the 33rd day of chemotherapy,the loss proportion of CD38 was higher than that in the 15th day（P<0.01）,and the gain proportion of CD34 was significantly higher than that in the 15th day（P<0.01）. In the 15th day, the loss proportion of CD10 was lower than those in the 33rd day and 48th day（P<0.05）. Most patients after chemotherapy had 1-4 antigens' expression changes. Conclusions After chemotherapy,the proportions of antigen positive rate and intensity changes for immuno-phenotypes are high in B-ALL patients. In the determination of MRD,it should consider phenotypes at primary diagnosis and their changes during chemotherapy.

Key words: Immuno-phenotype, Flow cytometry, B-lineage acute lymphoblastic leukemia

CLC Number:

R446.62

WANG Jiying, LIU Yan, SONG Zhen, SHANG Lei, CHEN Xuejing, ZHOU Chunlin, RU Kun, WANG Huijun. Comparison of minimal residual leukemia immuno-phenotypes at primary diagnosis and after chemotherapy in patients with B-lineage acute lymphoblastic leukemia[J]. Laboratory Medicine, 2016, 31(6): 467-473.

Figures/Tables 6

References 25

[1]	CAMPANA D, COUSTAN-SMITH E.Detection of minimal residual disease in acute leukemia by flow cytometry[J]. Cytometry, 1999, 38(4): 139-152.
[2]	KERST G,KREYENBERG H,ROTH C,et al.Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR[J]. Br J Haematol,2005,128(6):774-782.
[3]	BOROWITZ MJ,WOOD BL,DEVIDAS M,et al.Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232[J]. Blood,2015,126(8):964-971.
[4]	BENE MC,GRIMWADE D,HAFERLACH C,et al.Leukemia diagnosis:today and tomorrow[J]. Eur J Haematol,2015,95(4):365-373.
[5]	KARAWAJEW L,DWORZAK M,RATEI R,et al.Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia[J]. Haematologica,2015,100(7):935-944.
[6]	CAMPANA D,NEALE GA,COUSTAN-SMITH E,et al.Detection of minimal residual disease in acute lymphoblastic leukemia:the St Jude experience[J]. Leukemia,2001,15(2):278-279.
[7]	LUCIO P,GAIPA G,VAN LOCHEM EG,et al.BIOMED-I concerted action report:flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia:international standardization and clinical evaluation[J]. Leukemia,2001,15(8):1185-1192.
[8]	ORFAO A,CIUDAD J,LOPEZ-BERGES MC,et al.Acute lymphoblastic leukemia (ALL):detection of minimal residual disease (MRD) at flow cytometry[J]. Leuk Lymphoma,1994,13(Suppl 1):87-90.
[9]	WEIR EG,COWAN K,LEBEAU P,et al.A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry:implications for residual disease detection[J]. Leukemia,1999,13(4):558-567.
[10]	ZUR STADT U,HARMS DO,SCHLTER S,et al.MRD at the end of induction therapy in childhood acute lymphoblastic leukemia:outcome prediction strongly depends on the therapeutic regimen[J]. Leukemia,2001,15(2):283-285.
[11]	DELLA PORTA MG,PICONE C,PASCUTTO C,et al.Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes:results of a European Leukemia NET study[J]. Haematologica,2012,97(8):1209-1217.
[12]	BJRKLUND E,MAZUR J,SDERHLL S,et al.Flow cytometric follow-up of minimal residual disease in bone marrow gives prognostic information in children with acute lymphoblastic leukemia[J]. Leukemia,2003,17(1):138-148.
[13]	COUSTAN-SMITH E,SANCHO J,HANCOCK ML,et al.Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Blood,2000,96(8):2691-2696.
[14]	DWORZAK MN,FRSCHL G,PRINTZ D,et al.Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia[J]. Blood, 2002,99(6):1952-1958.
[15]	BOROWITZ MJ,PULLEN DJ,WINICK N,et al.Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia:implications for residual disease detection:a report from the children's oncology group[J]. Cytometry B Clin Cytom,2005,68(1):18-24.
[16]	DWORZAK MN,GAIPA G,SCHUMICH A,et al.Modulation fo antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient:evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group[J].Cytometry B Clin Cytom,2010,78(3):147-153.
[17]	GOMEZ E,SAN MIGUEL JF,GONZALEZ M,et al.Phenotypic changes in refractory and relapse acute lymphoblastic leukemias[J]. Sangre(Barc),1991,36(3):201-204.
[18]	COUSTAN-SMITH E,SONG G,CLARK C,et al.New markers for minimal residual disease detection in acute lymphoblastic leukemia[J]. Blood,2011,117(23):6267-6276.
[19]	SOLLY F,ANGELOT F,GARAND R,et al.CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry[J]. Cytometry A,2012,81(1):17-24.
[20]	DJOKIC M,BJRKLUND E,BLENNOW E,et al.Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia[J]. Haematologica,2009,94(7):1016-1019.
[21]	ARDJMAND A,DE BOCK CE,SHAHROKHI S,et al.Fat1 cadherin provides a novel minimal residual disease marker in acute lymphoblastic leukemia[J]. Hematology,2013,18(6):315-322.
[22]	WAANDERS E,VAN DER VELDEN VH,VAN DER SCHOOT CE,et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia[J]. Leukemia,2011,25(2):254-258.
[23]	MUZZAFAR T,MEDEIROS LJ,WANG SA,et al.Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry[J]. Am J Clin Pathol,2009,132(5):692-698.
[24]	BARTRAM CR,SCHRAUDER A,KHLER R,et al.Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment[J]. Dtsch Arztebl Int,2012,109(40):652-658.
[25]	IRVING J,JESSON J,VIRGO P,et al.Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting[J]. Haematologica,2009,94(6):870-874.

免疫表型	表达增强比例			表达减弱比例			表达强度改变比例			总比例
免疫表型	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	总比例
CD10	19.87	23.33	21.57	9.93	10.00	5.88	29.80	33.33	27.45	30.15
CD34	7.90	23.33	17.65	13.25	3.33	7.84	21.20	26.66	25.49	23.28
CD38	1.32	3.33	1.96	21.19	11.67	13.73	22.51	15.00	15.69	19.47
CD19	13.91	11.67	7.84	3.97	3.33	1.96	17.88	15.00	9.80	15.65
CD20	4.64	1.67	1.96	10.60	6.67	7.84	15.24	8.34	9.80	12.60
CD45	0.00	5.00	3.92	0.00	1.67	0.00	0.00	6.67	3.92	2.29
CD13+CD33^*	9.93	5.00	14.63	7.28	10.00	14.63	17.21	15.00	29.26

免疫表型	表达增强比例			表达减弱比例			表达强度改变比例			总比例
免疫表型	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	总比例
CD10	19.87	23.33	21.57	9.93	10.00	5.88	29.80	33.33	27.45	30.15
CD34	7.90	23.33	17.65	13.25	3.33	7.84	21.20	26.66	25.49	23.28
CD38	1.32	3.33	1.96	21.19	11.67	13.73	22.51	15.00	15.69	19.47
CD19	13.91	11.67	7.84	3.97	3.33	1.96	17.88	15.00	9.80	15.65
CD20	4.64	1.67	1.96	10.60	6.67	7.84	15.24	8.34	9.80	12.60
CD45	0.00	5.00	3.92	0.00	1.67	0.00	0.00	6.67	3.92	2.29
CD13+CD33^*	9.93	5.00	14.63	7.28	10.00	14.63	17.21	15.00	29.26

免疫表型	表型出现比例			表型消失比例			表型改变比例			总比例
免疫表型	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	总比例
CD20	7.95	8.33	9.80	26.49	18.33	13.73	34.44	26.66	23.53	30.53
CD38	1.32	0.00	1.96	18.54	41.67	39.22	19.86	41.67	41.18	29.00
CD34	1.99	13.33	3.92	9.93	6.67	0.00	11.92	20.00	3.92	12.21
CD45	7.28	1.67	3.92	5.30	5.00	7.84	12.58	6.67	11.76	11.07
CD10	0.00	1.67	0.00	3.31	13.33	15.69	3.31	15.00	15.69	8.40
CD19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CD13+CD33^*	0.66	2.50	0.00	15.89	22.50	21.39	16.55	25.00	21.39

免疫表型	表型出现比例			表型消失比例			表型改变比例			总比例
免疫表型	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	第15天（151例）	第33天（60例）	第48天（51例）	总比例
CD20	7.95	8.33	9.80	26.49	18.33	13.73	34.44	26.66	23.53	30.53
CD38	1.32	0.00	1.96	18.54	41.67	39.22	19.86	41.67	41.18	29.00
CD34	1.99	13.33	3.92	9.93	6.67	0.00	11.92	20.00	3.92	12.21
CD45	7.28	1.67	3.92	5.30	5.00	7.84	12.58	6.67	11.76	11.07
CD10	0.00	1.67	0.00	3.31	13.33	15.69	3.31	15.00	15.69	8.40
CD19	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
CD13+CD33^*	0.66	2.50	0.00	15.89	22.50	21.39	16.55	25.00	21.39